financetom
Business
financetom
/
Business
/
BMO Previews AGF Management's Q2
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BMO Previews AGF Management's Q2
Jun 20, 2024 11:08 AM

01:38 PM EDT, 06/20/2024 (MT Newswires) -- AGF Management reports its second quarter results on June 26.

BMO is looking for second quarter EBITDA of $35.3 million ($35.5 million consensus), and earnings per share of $0.34 (consensus $0.34).

Analyst Tom MacKinnon expects net outflows of $50 million, reflecting the challenging environment in the mutual fund industry.

"After recently increasing our go-forward EPS estimates 2.5% reflecting better clarity into the recent Kensington acquisition (closed March 8), we again slightly raise 2024E/2025E EPS estimates reflecting better-than-expected Q2/24 AUM and the impact of modest Q2/24 share buybacks."

AGF is rated Market Perform, with a $9 target.

Price: 8.45, Change: +0.01, Percent Change: +0.12

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cava Group Insider Sold Shares Worth $8,190,900, According to a Recent SEC Filing
Cava Group Insider Sold Shares Worth $8,190,900, According to a Recent SEC Filing
Jun 25, 2024
04:24 PM EDT, 06/25/2024 (MT Newswires) -- Theodoros Xenohristos, Director, on June 24, 2024, sold 90,000 shares in Cava Group ( CAVA ) for $8,190,900. Following the Form 4 filing with the SEC, Xenohristos has control over a total of 424,846 shares of the company, with 424,846 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1639438/000162828024029897/xslF345X03/wk-form4_1719346352.xml Price: 88.45, Change: -0.32, Percent Change: -0.36...
Allakos Reports 'Positive' Results From Phase 1 Trial of Antibody That Inhibits Mast Cells
Allakos Reports 'Positive' Results From Phase 1 Trial of Antibody That Inhibits Mast Cells
Jun 25, 2024
04:21 PM EDT, 06/25/2024 (MT Newswires) -- Allakos ( ALLK ) reported positive results late Tuesday from its single and multiple ascending phase 1 study of intravenous AK006, a monoclonal antibody that selectively inhibits mast cells, in healthy volunteers. The company said inappropriate activation of mast cells is a pathogenic driver of multiple diseases, including chronic spontaneous urticaria, food allergy,...
Atlassian Insider Sold Shares Worth $1,303,073, According to a Recent SEC Filing
Atlassian Insider Sold Shares Worth $1,303,073, According to a Recent SEC Filing
Jun 25, 2024
04:23 PM EDT, 06/25/2024 (MT Newswires) -- Scott Farquhar, 10% Owner, Director, Co-CEO, Co-Founder, on June 24, 2024, sold 7,948 shares in Atlassian ( TEAM ) for $1,303,073. Following the Form 4 filing with the SEC, Farquhar has control over a total of 31,792 shares of the company, with 31,792 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1650372/000156218024005288/xslF345X03/primarydocument.xml ...
Atlassian Insider Sold Shares Worth $1,303,074, According to a Recent SEC Filing
Atlassian Insider Sold Shares Worth $1,303,074, According to a Recent SEC Filing
Jun 25, 2024
04:23 PM EDT, 06/25/2024 (MT Newswires) -- Michael Cannon-Brookes, 10% Owner, Director, Co-CEO, Co-Founder, on June 24, 2024, sold 7,948 shares in Atlassian ( TEAM ) for $1,303,074. Following the Form 4 filing with the SEC, Cannon-Brookes has control over a total of 31,792 shares of the company, with 31,792 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1650372/000156218024005289/xslF345X03/primarydocument.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved